

Supplementary Table S1. Demographic characteristics of patients who started mycophenolate mofetil according to diagnosis.

	N (%)	Female (%)	Age mean \pm SD
SSc	35 (32)	32 (91)	61 \pm 16
ILD	24	24 (100)	
Myositis	1	1 (100)	
Skin disease	3	2 (67)	
Renal disease	1	1 (100)	
Constitutional symptoms/arthritis	1	1 (100)	
Haematologic involvement	1	0 (0)	
Intolerability/AE of other DMARDs	4	3 (75)	
SLE	18 (17)	17 (94)	53 \pm 19
ILD	2	2 (100)	
Myositis	1	1 (100)	
Alveolar haemorrhage	1	0 (0)	
Constitutional symptoms/arthritis	2	2 (100)	
Haematologic involvement	3	3 (100)	
Pulmonary hypertension	1	1 (100)	
Cystitis	1	1 (100)	
Peritonitis	1	1 (100)	
Vasculitis	1	1 (100)	
Intolerability/AE of other DMARDs	2	2 (100)	
PNS involvement	1	1 (100)	
CNS involvement	1	1 (100)	
IIM	17 (16)	9 (53)	58 \pm 20
ILD	8	4 (50)	
Myositis	4	3 (75)	
Skin disease	4	2 (59)	
Intolerability/AE of other DMARDs	1	0 (0)	
ASS	13 (12)	9 (69)	54 \pm 13
ILD	11	7 (64)	
Myositis	2	2 (100)	
SS	10 (9)	8 (80)	60 \pm 14
ILD	5	4 (80)	
Myositis	1	1 (100)	
Renal disease	1	1 (100)	
Constitutional symptoms/arthritis	1	1 (100)	
Ophthalmologic involvement	1	0 (0)	
PNS involvement	1	1 (100)	
IPAF	2 (2)	2 (100)	79 \pm 6
ILD	2	2 (100)	
UCTD	4 (4)	3 (75)	62 \pm 10
ILD	3	2 (67)	
PNS involvement	1	1 (100)	
MCTD	3 (3)	3 (100)	40 \pm 7
ILD	1	1 (100)	
Myositis	1	1 (100)	
Intolerability/AE of other DMARDs	1	1 (100)	
Overlap syndromes	5 (5)	3 (60)	66 \pm 20
ILD	4	2 (50)	
Myositis	1	1 (100)	
IgG4-RD	1 (1)	0 (0)	49
Idiopathic retroperitoneal fibrosis	1	0 (0)	
Total	108 (100)	86 (79.6)	58 \pm 17

SSc: systemic sclerosis; ILD: interstitial lung disease; AE: adverse events; DMARDs: disease-modifying antirheumatic drugs; SLE: systemic erythematosus lupus; PNS: peripheral nervous system; CNS: central nervous system; IIM: idiopathic inflammatory myopathies; ASS: antisynthetase syndrome; SS: Sjögren's syndrome; IPAF: interstitial pneumonia with autoimmune features; UCTD: undifferentiated connective tissue disease; MCTD: mixed connective tissue disease; IgG4-RD: IgG4 related disease.

Supplementary Table S2. Reasons for discontinuation of treatment with mycophenolate mofetil.

Reasons for discontinuation of treatment with MMF	N	(%)
Adverse events/intolerability	20	(53)
GI intolerability	12	
Cutaneous adverse drug reaction/Toxidermia/Pruritus	3	
Headache	1	
Infection	1	
Alopecia	1	
Leukopenia	2	
Lack of efficacy	6	(16)
Comorbidities	2	(5)
Neoplasia de novo diagnosis	1	
Pregnancy or plans of pregnancy	1	
Self-suspension	3	(8)
For unknown reasons	1	
For concern about SARS-CoV-2 infection	2	
Death	5	(13)
Unknown	2	(5)
Total	38	(100)

Supplementary Fig. S1. Survey.

MMF off-label use, a ReCONNET Survey

off-label use of mycophenolate mofetil (MMF) in the treatment of rheumatic connective tissue diseases

* Obrigatório

1. Name of your center *

2. Your name

As some centers might have multiple answers

3. How many patients with diffuse connective tissue disease were followed in your center during the last 5 years? *

O valor tem de ser um número

4. How many patients have been treated with MMF in your center during the last 5 years? *

O valor tem de ser um número

5. How many patients have been treated with MMF in your center during the last year? *

6. Select all the options that are indications you've used MMF in *

- ☐ Interstitial lung disease
- ☐ Skin disease
- ☐ Muscle involvement
- ☐ Central nervous system involvement
- ☐ Peripheral nervous system involvement
- ☐ Nephritis
- ☐ Other less frequent manifestations of connective tissue disease

7. Please specify

Specify which involvement and underlying disease (e.g. ILD in SSc)

8. Is Lupus Nephritis the most common indication for MMF off-label use in your center? *

- ☐ Yes
- ☐ No
- ☐ Not sure

9. Excluding Lupus Nephritis, select 2 other options you feel are the most frequent indications you've used MMF in *

- ☐ Interstitial lung disease
- ☐ Skin disease
- ☐ Muscle involvement
- ☐ Central nervous system involvement
- ☐ Peripheral nervous system involvement
- ☐ Other less frequent manifestations of connective tissue disease

10. Select the 3 top options that are indications you've used MMF most frequently in *

- ☐ Interstitial lung disease
- ☐ Skin disease
- ☐ Muscle involvement
- ☐ Central nervous system involvement
- ☐ Peripheral nervous system involvement
- ☐ Nephritis
- ☐ Other less frequent manifestations of connective tissue disease

11. If "other" please specify

12. Select the diagnoses in which you've used MMF *

- ☐ Idiopathic Inflammatory Myopathies
- ☐ Antisynthetase Syndrome
- ☐ Sjögren Syndrome
- ☐ Systemic Lupus Erythematosus
- ☐ Systemic Sclerosis
- ☐ IgG4-related disease
- ☐ Relapsing Polychondritis
- ☐ Other

13. If "other" please specify

14. Report the 5 diagnoses in which you've used MMF more frequently in order of frequency

select only the 5 more frequent diagnoses in your experience

	1st	2nd	3rd	4th	5th
Idiopathic Inflammatory Myopathies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Antisynthetase Syndrome	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Sjögren Syndrome	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Systemic Lupus Erythematosus	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Systemic Sclerosis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IgG4-related disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Relapsing Polychondritis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

15. If "other" please specify

16. Please name the specific uncommon diagnoses and disease involvement in which you've used MMF *

comment how many patients approximately you've treated with these diagnoses in the next question

17. How many patients approximately have you treated using MMF with the before mentioned uncommon diagnosis and disease involvement *

O valor tem de ser um número

18. In your expert opinion, does the majority of patients treated with MMF respond? *

- ☐ Complete response
- ☐ Partial response
- ☐ Stabilize
- ☐ Worsen

19. In your expert opinion, in the mentioned diagnoses, does the majority of patients treated with MMF respond? *

	Complete response	Partial response	Stabilize	Worsen
Idiopathic Inflammatory Myopathies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Antisynthetase Syndrome	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Sjögren Syndrome	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Systemic Lupus Erythematosus	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Systemic Sclerosis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
IgG4-related disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Relapsing Polychondritis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

20. In your expert opinion, in the mentioned disease involvement, does the majority of patients treated with MMF respond?

	Complete response	Partial response	Stabilize	Worsen
Interstitial lung disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Skin disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Muscle involvement	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Central nervous system involvement	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Peripheral nervous system involvement	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Nephritis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other less frequent manifestations of connective tissue disease	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

21. What are the most frequent causes for suspension of MMF in your center? *

(intolerance, adverse effects - please specify -, non-responsiveness,...)

22. How safe do you feel MMF is *

(1 - not safe at all with frequent adverse effects; 10 - safe drug, with very few adverse effects)

- 1 2 3 4 5 6 7 8 9 10
- ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐

23. Has the use of MMF increased in your center in the last couple of years? *

- ☐ Increased substantially
- ☐ Increased slightly
- ☐ Maintained
- ☐ Decreased slightly
- ☐ Decreased substantially